Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

IRRAS Secures Short-term Financing Agreement of MSEK 30

Stockholm, Sweden (May 19, 2022) – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced a short-term financing agreement with Bacara Holdings, its largest shareholder, which is led by the company’s Chairman of the Board of Directors, Marios Fotiadis.  This bridge loan agreement provides IRRAS up to MSEK 30 in funding to cover its working capital needs until the completion of the company’s ongoing financing process, which is intended to secure sufficient funds to support growth for at least 18

Scandion Oncology – Interim Report Q1 2022

Scandion Oncology (Scandion) today announces its interim report for Q1 2022. The following is taken from the report.Bo Rode Hansen, President and CEO, comments “It is with pleasure that we report on our activities for the first quarter of 2022. It has been a good start to the year with solid operations, continued execution of our strategy and implemen­tation of our plans. I am looking at a company “punching above its weight” in several ways.” Key Figures & Highlights TDKK Q1 2022 Q1 2021 FY 2021 Operating loss -16,312 -9,904

Interim Report January-March 2022

ChromoGenics increased its net sales and completed a rights issue for SEK 54.4 million to accelerate growthQ1 2022 · In Q1 2022, ChromoGenics’ net sales amounted to SEK 8.5 (1.6) million, an increase of SEK 6.9 million compared to the corresponding quarter in 2021. · The operating loss for Q1 2022 amounted to SEK -16.8 (-9.8) million. Earnings were burdened by approximately SEK 3.9 million due to reduced delivery capacity from subcontractors that led to increased costs and other disruptions in the supply chains that resulted in additional increases to logistics costs.  · During

Clinical Laserthermia Systems AB publishes interim report January – March 2022

Summary of the interim report (relates to the Group) Three months (01/01/2022 – 03/31/2022) · Net sales amounted to SEK 708,000 (SEK 893,000). · Profit/loss after financial items amounted to SEK -13.824 million (SEK -9.461 million). · Basic and diluted earnings per share amounted to SEK -0.21 (SEK -0.21). · The equity/assets ratio was 12% (7%) on March 31, 2022.   Significant events in the first quarter of 2022 · CLS and Skåne University Hospital initiated a collaboration to conduct a clinical study of MR image-guided laser ablation treatment of glioblastoma

Clinical Laserthermia Systems AB publicerar delårsrapport januari – mars 2022

Sammanfattning av delårsrapporten (avser koncernen) Tre månader (2022-01-01 – 2022-03-31) · Nettoomsättning uppgick till 708 KSEK (893 KSEK). · Resultatet efter finansiella poster uppgick till -13 824 KSEK (-9 461 KSEK). · Resultatet per aktie före och efter utspädning uppgick till -0,21 SEK (-0,21 SEK). · Soliditeten uppgick per den 31 mars 2022 till 12 % (7 %).   Väsentliga händelser under första kvartalet 2022 · CLS och Skånes universitetssjukhus inledde ett samarbete för att genomföra en klinisk studie avseende MR-bildledd laserablationsbehandling av

Dignitana AB Publishes Q1 2022 Interim Report

Solid growth trend continues at 21 percent Financial highlights Q1 2022 · Net sales amounted to 15.9 MSEK (13.2), an increase of 21 percent over the same period in 2021. · Operating result amounted to -6.1 MSEK (-7.1). ·Net result after financial items amounted to -6.5 MSEK (-7.7). ·Earnings per share were -0,10 SEK (-0,12). ·Cash Balance amounted to 11.3 MSEK (44.4). ·Average Daily Treatment Revenue (ADTR)* was 179 TSEK (130), an increase of 38 percent over the same period in 2021. Significant events during the period ·The Board appointed

A GOOD START AND FOCUS ON THE FUTURE

This is a translation of the Swedish interim report. If there should be any discrepancies, the Swedish language version governs. FIRST QUARTER, JANUARY– MARCH 2022 · Net sales increased by 11.6%, or 9.6% FX adjusted, to MSEK 79.9 (71.6) · Gross profit increased by 15.4%, or 12.9% FX adjusted, to MSEK 62.1 (53.8) · EBIT increased to MSEK 8.9 (6.5) · Earnings after tax was MSEK 7.9 (7.3) · Earnings per share was SEK 1.00 (0.93) IMPORTANT EVENTSDURING THE PERIOD       · As previously communicated, the monetary effects of the war in Ukraine have been limited to a

Metso Outotec launches modular Converter Hood System for efficient gas capture in smelting plants with converter solutions

Metso Outotec Corporation’s press release on May 19, 2022, at 09:00 a.m. EESTMetso Outotec is launching a modular Converter Hood System for horizontal converter vessels used in the smelting process. The new system, which is suitable for greenfield and brownfield installations, has an impressive SO\2\ (sulfur dioxide) gas capture capability of 99%, minimizing the environmental impact. The modular design enables quick on-site assembly, so the system is ready to use with minimum plant downtime. “We are excited to launch the new Converter Hood System. Besides its excellent gas capture

Bricknode interim report Q1 2022

Bricknode has today published its interim report for the period January – March 2022. The report is attached to this press release and is available on the company’s website .Q1 2022 in brief · Net revenue increased by 24% to 4,671 (3,765) TSEK · Net revenue retention rate 107 (103)% · Earnings per share amounted to -0,41 (-0,13) SEK · EBIT result amounted to -3,962 (-908) TSEK and the margin amounted to -85% (-24%) · Agreement signed with B2B lending company Comments from the CEOs, Stefan Willebrand & Erik

EasyFill AB (publ) signs license agreement with HL Display AB

EasyFill has today signed a license agreement with HL Display AB regarding licensing of EasyFill TurnLoader and RotoShelf for refrigerated multideck cabinets and cold rooms.The purpose of the agreement gives HL Display exclusive distribution rights in Europe for EasyFill's patented solutions RotoShelf and TurnLoader for applications in refrigerated multidecks and cold rooms. HL Display will take care of all sales of these products to the end customers and to EasyFill's existing OEM partners. This is a deepening of the existing collaboration between the companies that provides synergies

Q1 interim report January – March 2022

Collections in line with last year whilst earnings were affected by market volatilityHighlights first quarter 2022 · Gross ERC at the end of March 2022 was EUR 298m (299 at December 2021) · Cash at the end of March 2022 was EUR 62.7m (65.5 at December 2021) · Gross collections amounted to EUR 16.1m (15.7)* · Net collections amounted to EUR 13.1m (13.9)* · Cash EBITDA amounted to EUR 11.6m (11.2)* · Net loss for the period of EUR 1.7m (profit of 0.3)* including EUR 3.4m mark-to-market loss on the investment in Addiko Bank driven by the proposed CHF law in Slovenia and

Q1 interim report January – March 2022

Collections in line with last year whilst earnings were affected by market volatilityHighlights first quarter 2022 · Gross ERC at the end of March 2022 was EUR 296m (297 at December 2021) · Cash at the end of March 2022 was EUR 60.4m (62.7 at December 2021) · Gross collections amounted to EUR 15.7m (14.4)* · Net collections amounted to EUR 12.7m (12.6)* · Cash EBITDA amounted to EUR 11.8m (10.1)* · Net loss for the period of EUR 1.0m (0.2)* including EUR 3.4m mark-to-market loss on the investment in Addiko Bank driven by the proposed CHF law in Slovenia and market

Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map[®] in the United Arabic Emirates (UAE) market

OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd. (“Omnigene"), a Malta-based biotechnology company, providing advisory services within several therapeutic areas as cancer and neuroscience. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test, a CE-marked standardized gut microbiome test as a service to the UEA market.Gut microbiome profiling is increasingly required in the field of precision

Balder performs share split (6:1) and resolves record date

At the Annual General Meeting of Fastighets AB Balder (publ) (”Balder”) on 12 May 2022, it was decided to divide the company’s shares, whereby each share, regardless of share class, is divided into six (6) new shares (share split 6:1). The Annual General Meeting further resolved to authorize the Board to determine the record date (Sw. avstämningsdag) for the share split. Balder’s Board of Directors has today, with the support of the authorization, resolved that the record date for the share split shall be 27 May 2022. Schedule for the division:24 May 2022: Last day for trading before

Gradientech: Interim report January 1 – March 31, 2022

Gradientech AB (publ) interim report for Q1 2022 is now available on the company's website www.gradientech.se.First quarter January-March 2022 · Net sales amounted to 0 KSEK (0 KSEK). · Net profit amounted to SEK -15,171 KSEK (-9,969 KSEK). · Earnings per share before dilution were SEK -1.04 (SEK -0.82). · Earnings per share after dilution were SEK -0.99 (SEK -0.82). · Cash flow from operating activities amounted to -14,886 KSEK (-14,702 KSEK). · Cash and cash equivalents on the balance sheet date amounted to 74,033 KSEK (55,612 KSEK). · Equity as of March 31 amounted

Financial Report 1st quarter for DOF ASA

The Group's revenue for 1st quarter (management reporting) totals NOK 2,174 million (NOK 1,514 million) and EBITDA totals NOK 767 million (NOK 492 million). The operating profit (EBIT) is NOK 321 million (NOK 45 million), of which depreciation and impairment totals NOK 446 million (NOK 447 million).  Net financial cost amounts to NOK 630 million (NOK -720 million) including unrealised currency gain of NOK 1,010 million (NOK -480 million). The profit is NOK 824 million (NOK -801 million). Key information: Operations · Average utilisation of the fleet in 1[st] quarter was 82% (67%).

Hemsö and Hoivamme develop a nursing home portfolio of EUR 50 million

Hemsö has formed a strategic partnership with the Finnish care operator Hoivamme, which provides elderly care. Hemsö and Hoivamme have signed a framework agreement whereby Hemsö finances the development projects and will become the long-term owner of the properties. Hoivamme will sign 15-year leases for the completed properties.The companies' current agreement involves the construction of 10–12 nursing homes with a total investment of EUR 50 million. The parties have already agreed for four properties which are currently under construction and will be completed during 2022-2023. Hemsö's

Acroud publishes interim report Jan-Mar 2022: Strong organic growth with the right forward momentum

First Quarter 2022 · Revenue amounted to EUR 7 003 (5 579) thousand, corresponding to a growth of 26% (75%) and an organic growth of 15.5% (-9.7%).    · EBITDA amounted to EUR 2 248 (1 441) thousand. Adjusted EBITDA (before items affecting comparability) was EUR 1 781 (1 575) thousand.    · Profit after tax was EUR 1 184 (748) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR 551 (553) thousand.    · Earnings per share after dilution amounted to EUR 0.009 (0.006). Adjusted earnings per share (before items

Nel ASA: EU Commission increases ambitions on renewable hydrogen

(Oslo, 19 May 2022) Yesterday the European Commission presented a wide range of initiatives to reduce Europe’s reliance on fossil fuels from Russia. A list of proposals aimed to stimulate the production of renewable hydrogen and to improve framework conditions for European electrolyser manufacturers are included in this plan, known as RePowerEU.These proposals include: 1. A call to the co-legislators (European Parliament and the Council) to increase the demand side targets for the use of renewable hydrogen in certain sectors, specifically: · an increase in the industry target from

Intervacc progresses vaccine to prevent mastitis in dairy cows caused by Staphylococcus aureus

Stockholm, May 19, 2022 - Intervacc AB (publ) announces the initiation of a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by Staphylococcus aureus following successful safety and immunogenicity studies testing this prototype vaccine in pregnant heifers. This next phase of the project will be receiving a grant of 80k Euro from the EU’s VetBioNet initiative. Mastitis is one of the most important diseases of dairy cattle worldwide. Over 2.6 million cases of disease, causing losses of approximately 600M€, occur in European

Cereno Scientific publishes interim report for Q1 2022

The Board and Chief Executive Officer of Cereno Scientific AB here presents the interim report for Q1, 1 January – 31 March, 2022. Summary of the first quarter, January – March 2022Cereno Scientific Group First quarter (1 January – 31 March 2022) · Net Sales were SEK 0 (0) · Result after financial items was SEK -5,246,969 (-3,903,947) · Earnings per share was SEK -0.05 (-0.05) before dilution and SEK -0.04 (-0.03) after dilution · The equity/assets ratio was 93.4% (87.2%) · Cash and bank balance was SEK 77,268,668 (60,071,685) Parent company First quarter (1

ArcticStartup raises funding from celebrity investors like GaryVee

With new startup conferences in new locations and the launch of a new deep tech focused community, ArcticStartup aims to be a leading matchmaker for investors and startups.HELSINKI, Finland (May 19, 2022) ArcticStartup , organizer of Arctic15 , the key matchmaking startup conference in the Nordics and Baltics, has concluded a successful bridge funding round as it resumes physical events for the first time post-pandemic. With the fresh funding, ArcticStartup will take its winning startup event and ecosystem-building concept to the world,

SRV Group Plc: Managers' transactions – Tomi Yli-Kyyny

SRV GROUP PLC       MANAGERS' TRANSACTIONS   19 May 2022     08.50 EEST SRV Group Plc: Managers' transactions – Tomi Yli-Kyyny Notification under the EU Market Abuse Regulation, article 19 SRV Yhtiöt Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tomi Yli-Kyyny Position: Member of the Board/Deputy member Issuer: SRV Yhtiöt Oyj LEI: 743700GB29FXC0VXF414 Notification type: INITIAL NOTIFICATION Reference number: 15217/4/4 ____________________________________________

There are no items matching the current filter
There are no more items matching the current filter
Back to top